PS5 console covers will also be available in all three Hyperpop Collection colors. These will be available for both the ...

CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and strategic changes. Analyst John Athanasiou from Red Leaf Securities suggests CSL shares are oversold, ...

Accusing CSL of a “disgraceful” approach to bargaining, the CSL Behring workers are taking the protected action as the company puts out a revised offer to workers following the voting down of a ...

CSL's share price has declined by 35% in 2025, influenced by a challenging US healthcare industry and cautious growth prospects. Despite headwinds, UBS sees potential medium-term recovery, especially ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...

SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company is also closing two ...

Plans to spin off CSL Seqirus into listed entity by next June Seeks annualised savings of up to $550 million over three years Lifts dividend and plans A$750 million share buyback Underlying profit up ...